Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 126 participants.

Also called NCT01726816

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 126 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01726816
Other papers using this trial's data
  • Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial Arteriosclerosis, thrombosis, and vascular biology, 2016-10 DOI, PubMed 27493100

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01726816. Randomized; double masking; primary purpose treatment. Start 2012-10 (registry gives no type); primary completion 2014-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy
Condition
Diabetic Nephropathy
Intervention (Drug)
Probucol 250mg/day
Intervention (Drug)
Probucol 500mg/day
Intervention (Drug)
Placebo
Lead sponsor
Korea Otsuka Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct01726816
Content hash
ac15c7b7313d4411aefeee4bfa1675cdb07e3e50556966dd7eb6b6dda5acaf17